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The material-enabled oxygen control in thiol-ene
microfluidic channels and its feasibility for
subcellular drug metabolism assays under hypoxia
in vitro†
Iiro Kiiski, a Päivi Järvinen, a Elisa Ollikainen,a
Ville Jokinen b and Tiina Sikanen *a
Tissue oxygen levels are known to be critical to regulation of many cellular processes, including the hepatic
metabolism of therapeutic drugs, but its impact is often ignored in in vitro assays. In this study, the
material-induced oxygen scavenging property of off-stoichiometric thiol-enes (OSTE) was exploited to
create physiologically relevant oxygen concentrations in microfluidic immobilized enzyme reactors (IMERs)
incorporating human liver microsomes. This could facilitate rapid screening of, for instance, toxic drug
metabolites possibly produced in hypoxic conditions typical for many liver injuries. The mechanism of
OSTE-induced oxygen scavenging was examined in depth to enable precise adjustment of the on-chip
oxygen concentration with the help of microfluidic flow. The oxygen scavenging rate of OSTE was shown
to depend on the type and the amount of the thiol monomer used in the bulk composition, and the
surface-to-volume ratio of the chip design, but not on the physical or mechanical properties of the bulk.
Our data suggest that oxygen scavenging takes place at the polymer-liquid interface, likely via oxidative
reactions of the excess thiol monomers released from the bulk with molecular oxygen. Based on the
kinetic constants governing the oxygen scavenging rate in OSTE microchannels, a microfluidic device
comprising monolithically integrated oxygen depletion and IMER units was designed and its performance
validated with the help of oxygen-dependent metabolism of an antiretroviral drug, zidovudine, which yields
a cytotoxic metabolite under hypoxic conditions.
Introduction
Oxygen partial pressure is an essential parameter in many
biological processes in the human body, including signaling
pathways affecting, e.g., stem cell differentiation1 and cancer
pathophysiology.2 The physiological oxygen levels vary from
10–13% in the arteries and lungs (most oxygenated tissues) to
1–4% in the liver and colon.3 Oxygen also plays a crucial role
with respect to the safety and efficacy of therapeutic drugs, as
their hepatic clearance (metabolism) may be oxygen-
dependent. For example, the optimum oxygen concentration
of cytochrome P450 (CYP) enzymes, which are the main
elimination pathway for majority of therapeutic drugs,4 is
known to be enzyme-dependent and different between drug
substrates.5,6 Under normoxic conditions in the liver (4%
O2),
2,3 oxygen is not the limiting factor with respect to drug
clearance, because the half-maximal CYP activity (KO2) is
typically reached at oxygen concentrations in the range of 10
μM (1%).5,6 However, upon aging and in the context of liver
diseases, the hepatic oxygen uptake may be impaired and
lead to deficient metabolic clearance (therapeutic level
exceeded)7 or formation of cytotoxic metabolites only
produced in hypoxic conditions.8–10 The current state-of-the-
art in vitro techniques are well established for high-
throughput screening of metabolites using human liver
microsomes (vesicle-like artifacts of the endoplasmic
reticulum) under atmospheric oxygen pressure, but the
impact of oxygen on drug metabolism is much less explored.
The oxygen concentration in cell cultures can be controlled
using hypoxia incubators,11 but these do not enable rapid
changes in the oxygen levels and are thus not well feasible for
identification of hypoxic metabolites in short-term (<1 h)
incubations on microsomal enzymes.12 Even more
demanding is the rapid screening of the impact of oxygen
concentration on the metabolic profile of a drug compound
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in a cost-effective manner. As a result, the largely ignored
hypoxic metabolites of new drug candidates may give rise to
unexpected hepatotoxicity in clinical trials or even post-
marketing. Bridging this technology gap would substantially
improve the preclinical in vitro–in vivo extrapolation of drug
safety and efficacy.13
In recent years, increasing number of microfluidic oxygen
modulation approaches have been developed to improve the
control of oxygen microenvironment, primarily in cell-based
in vitro assays.14,15 The microfluidic platforms often rely on
multi-compartment designs comprising a cell culture assay
unit and an “oxygen control” unit, typically separated by a
gas-permeable membrane to enable precise adjustment of
the gas composition via controlled oxygen diffusion through
the membrane.16–18 The gas content of the oxygen control
compartment is usually adjusted by an external gas
supply17,19 or supplementary reducing agents, such as
sodium sulfite.18,20,21 While these approaches enable precise
control of the oxygen microenvironment, they often require
massive auxiliary instruments (external gas regulators and
off-chip mixers) or the use of reagents that are not only
highly reactive with molecular oxygen but also prone to
attack biological macromolecules.
Recently, microfluidic devices made of off-
stoichiometric thiol-enes (OSTE) were shown to possess an
inherent capacity for depleting oxygen from aqueous
media,22 which could be used as an alternative to
supplementary oxygen scavengers, thus enabling
substantially simpler microfluidic chip designs. OSTE
refers to a group of polymers prepared via UV-initiated
radical reaction between monomers containing thiol and
allyl (‘ene’) functional groups.23 Using thiol and allyl
monomers in an off-stoichiometric ratio enables
straightforward tuning of both the surface and bulk
properties of the resulting polymer.24 This facilitates, for
instance, straightforward bonding25 and further surface
biofunctionalization via click chemistry.24 In the previous
work, also the inherent oxygen scavenging capability was
associated with the use of thiol excess in the bulk
polymer.
In the present study, the mechanistic basis of OSTE-
induced oxygen scavenging was examined in detail with the
aim of establishing in-depth understanding of the rate-
limiting steps and deriving the kinetic constants that govern
oxygen depletion in OSTE-based microfluidic channels
prepared by UV-replica molding in the absence of
photoinitiators or other additives. With the help of the
kinetic constants, new design principles were drawn for OSTE
microdevices so that normoxic and hypoxic conditions could
be reproduced on demand in a single microfluidic biological
experiment. As a proof-of-concept, an OSTE-based
microfluidic device comprising two monolithically integrated
compartments, an oxygen depletion unit and an immobilized
enzyme reactor (IMER) unit, was designed and its
performance validated with the help of the oxygen-dependent
metabolism of an antiretroviral drug, zidovudine.
Experimental
Materials and reagents
The monomers used for fabricating the microfluidic chips
included pentaerythritol tetrakis(3-mercaptopropionate)
(PETMP) (≥95.0%), trimethylolpropane tris(3-
mercaptopropionate) (TMPTMP) (>95.0%), and triallyl-1,3,5-
triazine-2,4,6(1H,3H,5H)-trione (TATATO) (≥98.0%), and were
purchased from Sigma-Aldrich (St. Louis, MO; TMPTMP,
TATATO) or Bruno Bock (Marschacht, Germany; ThioCure®
PETMP). The microchip masters were fabricated from SU-8
100 (micro resist technology, Berlin, Germany) and the
poly(dimethyl siloxane) (PDMS) molds from Sylgard 184
(Down Corning Corporation, Midland, MI).
Magnesium chloride, biotin-PEG4-alkyne, ethylene glycol,
5,5-dithio-bis-(2-nitrobenzoic acid) (DTNB), β-nicotinamide
adenine dinucleotide 2′-phosphate (NADPH) reduced
tetrasodium salt hydrate, uridine 5′-diphosphoglucuronic
acid trisodium salt (UDPGA), Trizma® base and phosphate
buffered saline (PBS, pH 7.4) were purchased from Sigma
Aldrich. Zidovudine (AZT), zidovudine glucuronide (AZT-G)
and 3′-amino-3′-deoxythymidine (AMT) were from Toronto
Research Chemicals (Ontario, Canada). Irgacure® TPO-L
photoinitiator (ethyl phenyl[2,4,6 trimethylbenzoyl]
phosphinate, 84 434-11-7) was obtained from BASF
(Ludwigshafen, Germany). Streptavidin (Alexa Fluor® 488
conjugate) was from Life Technologies (Eugene, OR) and the
lipids used for preparation of fusogenic liposomes were from
Avanti Polar Lipids (Alabaster, AL), including 1,2-dioleoyl-3-
trimethylammonium-propane (chloride salt) (DOTAP),
1,2-dioleoyl-sn-glycero-3-phophoethanolamine (DOPE),
1,2-dioleoyl-sn-glycero-3-phophoethanolamine-N2 (Cap-
biotinyl) (sodium salt) (biotin-cap-DOPE) and 1,2-dioleoyl-sn-
glycero-3-phosphoethanolamine-N-(lissamine rhodamine B
sulfonyl) (ammonium salt) (lissamine rhodamine B-DOPE).
The human liver microsomes (HLM, Corning® Gentest, 20-
Donor Pool) were from Corning (Wiesbaden, Germany). All
chemicals were of analytical grade unless otherwise stated.
Water was purified with a Milli-Q water purification system
(Millipore, Molsheim, France).
Fabrication of off-stoichiometric thiol-ene microfluidic chips
The microchip designs used in the oxygen depletion assays
included “unpacked” rectangular microchannels (30 × 2 × 0.2
mm) with surface-to-volume ratio of A/V ≈ 6 mm−1 (73 mm2/
12 mm3), and microchannels (30 × 4 × 0.2 mm) comprising
an array of ca. 14 400 micropillars (Ø 50 μm, in a hexagonal
lattice with center-to-center interpillar distance of 100 μm)
with A/V ≈ 30 mm−1 (691 mm2/23 mm3). The
microfabrication protocol (Fig. 1) consisted of the following
four steps: (i) microfabrication of SU-8 masters by
photolithography, (ii) soft lithography of the PDMS molds
with the help of the SU-8 masters, (iii) UV-replica molding of
the microchannel and cover layers in OSTE with the help of
the PDMS molds, and (iv) bonding of the two OSTE layers
together by lamination. The SU-8 master (step i) was
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fabricated similar to previous work.26 The PDMS molds (step
ii) were prepared by mixing the base elastomer and the
curing agent in a weight ratio of 10 : 1, casting the
prepolymer onto the SU-8 master and curing in the oven
either at 80 °C for 3 h or at 65 °C overnight before detaching
the PDMS mold from the SU-8 master. The preparation of the
OSTE layers (step iii) consisted of mixing the thiol (TMPTMP
or PETMP) and allyl (TATATO) monomers and casting the
mixture on the PDMS mold, before curing under UV for 5
min (Dymax 5000-EC series UV flood exposure lamp, nominal
power 225 mW cm−2, Dymax Corporation, Torrington, CT).
After UV-curing, the two layers were detached from the PDMS
mold, heated above their glass transition temperature in the
oven (ca. 60–70 °C), laminated together, and exposed to UV
through the cover layer for 2 min to finalize the bonding
(step iv). The structural fidelity of the microfluidic chips was
investigated using a FEI Quanta™ 250 FEG scanning electron
microscope (Hillsboro, OR). For this purpose, the samples
were attached onto the sample stage with a carbon-coated
double-sided tape and sputtered with platinum for 25
seconds (30 mA) yielding a 5 nm-thick coating.
Differential scanning calorimetry
The glass transition temperatures (Tg) of native and heat
treated (110 °C overnight) OSTE polymers were determined
with DSC 823e differential scanning calorimeter (Mettler-
Toledo, Switzerland) using nitrogen as the purge gas. For this
purpose, OSTE polymer of the chosen composition was cured
against the PDMS mold, cut manually to suitably small
pieces, and one representative sample per composition was
analyzed. The Tg determination consisted of three steps: 1)
cooling the sample to −35 °C, 2) isothermal sequence at −35
°C for 3 min, and 3) heating from −35 °C to 100 °C at a rate
of 20 °C min−1. The glass transition temperatures were
determined using STARe software.
Oxygen permeability
For oxygen permeability measurements, thin OSTE
membranes were fabricated by pipetting a small amount of
the uncured monomer mixture of the chosen composition
between two microscope glass slides (25 × 75 mm2) pre-
coated with PDMS (base elastomer-curing agent 10 : 1, w/w)
by spincoating (4000 rpm, 60 s). The glass slides were fixed
together by two layers of Scotch double-sided tape, resulting
in an interplate gap of ca. 100–200 μm, which defined the
thickness of the OSTE membrane. The OSTE membranes
were cured through the glass plate under UV for 5 min
(Dymax) and then carefully detached from the PDMS coated
glass slides. The oxygen flux (cc m−2 per day) through the
membrane at 37 °C (100% humidity) was determined twice
for each sample (two replicates of each composition) using
an 8101e OxySense® oxygen transmission rate analyzer
Fig. 1 Molecular structures of the thiol (TMPTMP or PETMP) and allyl (TATATO) monomers used for fabricating the microfluidic chips and
schematic illustration of the microfabrication workflow: (i) patterning of the negative photoresist SU-8 through a photomask, (ii) replica molding of
PDMS negative mold using the SU-8 master, (iii) UV-induced replica molding of OSTE using the PDMS mold, and (iv) UV-induced bonding of OSTE
layers. The color gradient in OSTE parts visualizes the monomer migration within the bulk and the resultant gradient in the chemical composition
of the bulk polymer: intense orange indicates low crosslinking degree (high concentration of uncrosslinked monomers) and faint orange indicates
high crosslinking degree (low concentration of uncrosslinked monomers). TMPTMP = trimethylolpropane tris(3-mercaptopropionate), PETMP =
pentaerythritol tetrakis(3-mercaptopropionate), TATATO = triallyl-1,3,5-triazine-2,4,6(1H,3H,5H)-trione.
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equipped with a coulometric detector (Systech Instruments
Ltd, Thame, UK). The average oxygen permeability (cc cm
m−2 per day atm−1) of the four technical replicates per
composition was then calculated accounting for the
measured thickness of the membrane.
Oxygen level measurements
Oxygen levels inside the microchannels were monitored with
the help of commercial nanoparticles incorporating a
fluorescent indicator dye (OXNANO, Pyro Science, Aachen,
Germany), diluted to 1 mg mL−1 particle concentration in de-
ionized MQ water (feed solution). The fluorescence lifetime
of the particles was measured through the optically
transparent OSTE layer using a Piccolo2 oxygen meter (Pyro
Science, Aachen, Germany), as illustrated in Fig. 2A and B.
Before use, a two-point calibration (0% and 100% air
saturation) of the oxygen meter was performed according to
the manufacturer's instructions using glucose oxidase (0.1
mg mL−1) and glucose (10 mg mL−1) to obtain oxygen-free
water. Following this protocol, the nominal detection limit of
the sensor was 0.1% and the resolution 0.05% (air
saturation). With a view to biological applications, all
measurements were performed at physiological temperature
(37 °C) using an aluminum heating block element affixed
under the OSTE chip. The temperature on top of the chip
was monitored with a thermocouple and kept at the target
temperature with the help of proportional–integral–derivative
(PID) controller.
The effects of monomer type (TMPTMP or PETMP) and
bulk polymer composition as well as the impacts of different
post-fabrication treatments on oxygen depletion rates were
first determined in static conditions using rectangular thiol-
ene channels (2 × 30 × 0.2 mm) fabricated as described above
and bonded onto a glass substrate. The microchannels (n =
4–8 each composition/treatment) were filled with the
OXNANO nanoparticle solution, the channel openings were
carefully sealed with Parafilm (Bemis Company, Oshkosh,
WI), and the oxygen concentration was measured through
the cover layer at five different locations along the channel
length at indicated time points. To ensure a saturated
environment, the channel was kept under a Petri dish cover
with moistened paper.
To study oxygen scavenging under flow-through
conditions, the microchannels were connected to a syringe
pump using commercial nanoports (IDEX Corp., Lake Forest,
IL) and 3D-printed nanoport holders prepared in-house. The
instant oxygen concentration on chip was measured by
Fig. 2 Oxygen depletion in OSTE microchannels in static conditions. (A) A photograph and (B) schematic of the measurement setup used for
determining the on-chip oxygen concentration in the OSTE channels in static conditions with the help of OXNANO particles. (C–E) The oxygen
scavenging kinetics in crosslinked, rectangular thiol-ene microchannels (30 × 2 × 0.2 mm) fabricated using stoichiometric and thiol-rich (+50
mol%) bulk compositions made of (C) tetrafunctional PETMP or (D) trifunctional TMPTMP as the thiol component and TATATO as the allyl
component. HT refers to heat treatment (110 °C, overnight) after UV-curing. (E) The oxygen scavenging kinetics in crosslinked rectangular thiol-
ene microchannels fabricated using either thiol-rich (+25 mol%) or allyl-rich (+25 mol%) bulk compositions made of PETMP and TATATO. PI refers
to added photoinitiator (Irgacure® TPO-L, 0.1% m/v) in the bulk composition. Data points are averaged from n = 5 measurements per time point
from n = 4–8 individual microchannels per sample group. The standard error between replicates was within 0.2–7.4% RSD, but due to the
logarithmic scale the error bars are not visible.
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increasing the flow rate step-wise from 2.5 to 20 μL min−1 as
soon as the system reached steady state. The total duration
of the flow-rate experiment was ca. 2.5 h.
In addition to crosslinked OSTE chips, the oxygen
scavenging ability of free TMPTMP and PETMP monomers
was separately examined by dissolving either monomer at
different concentrations with the OXNANO nanoparticles (0.5
mg mL−1) in de-ionized water. In this case, the test solution
(1 mL) was placed in a 1.5 mL Eppendorf tube and the
oxygen level over time was measured through the wall of the
tube using the Piccolo2 oxygen meter.
Quantitation of thiol monomers in OSTE microchannels
The amount of thiol monomers released from the bulk OSTE
polymer into the microchannel per time was quantitated by
titration using Ellman's reagent (5,5′-dithiobis[2-nitrobenzoic
acid], DNTB).27 These experiments were performed with
micropillar arrays (n = 6, A/V ≈ 30 mm−1) fabricated from
PETMP containing composition with 25% molar excess of
thiol functional groups over allyl functional groups. First, the
free surface thiols were passivated by incubating a 1 mM
DNTB solution (aq) in the channel for 30 min in static
conditions. Next, a fresh DNTB solution was fed into the
microchannel and incubated in the channel for 10, 20, or 30
min in static conditions, after which the reaction product,
2-nitro-5-thiobenzoate (TNB), produced in an equimolar ratio
compared with free thiol functional groups, was quantitated
by UV absorbance (λ = 412 nm) using Varioskan LUX
Microplate Reader (ThermoScientific, Vantaa, Finland). The
concentration of the thiol functional groups was determined
using a molar extinction coefficient of ε = 14 150 M−1 cm−1
for TNB28 and the in-built pathlength correction function of
Varioskan LUX.
Fabrication and functionalization of the micropillar arrays
for on-chip drug metabolism assays
For conducting drug metabolism assays under flow-through
conditions on-chip, a microdevice with monolithically
integrated oxygen depletion and immobilized enzyme
microreactor (IMER) units was designed and fabricated from
PETMP and TATATO containing composition with 25% molar
excess of thiol over allyl functional groups. The oxygen
depletion unit comprised of six serially connected micropillar
channels of the same type as those used in the oxygen
depletion assays. The IMER unit was a similar micropillar
array and was serially connected, as the seventh element,
with the oxygen depletion unit through a Y-junction. The
micropillars of the IMER unit were functionalized
sequentially with biotin, streptavidin, and pre-biotinylated
HLM similar to the previous work.26 The first biotin layer was
achieved by crosslinking biotin-PEG4-alkyne (0.1 mM in
ethylene glycol, with 1% Irgacure® TPO-L) with the surface
thiols under UV for 1 min (λ = 365 nm, LED, nominal
intensity 14 mW cm−2). After rinsing sequentially with
methanol and water (≥5 mL each), the micropillar array of
the IMER unit was filled with 0.5 μg mL−1 streptavidin (in
PBS), incubated at room temperature for 30 min and rinsed
with ≥5 mL PBS. Last, the micropillar array of the IMER unit
was filled with pre-biotinylated human liver microsomes (b-
HLM), prepared as described by in the previous work.30 Next,
the inlets and outlets were sealed with Parafilm and the
b-HLM was allowed to immobilize onto the streptavidin-
coated micropillars at 4 °C overnight. Before use, the
micropillar array of the IMER unit was rinsed with the run
buffer (0.1 mM Tris buffer, 5 mM MgCl2, pH 7.5), after which
the entire integrated chip was filled with fresh run buffer.
Microfluidic drug metabolism assays under controlled
oxygen environment
The drug metabolism assays were performed with the
integrated chip design comprising of the oxygen depletion
and the IMER units using an antiretroviral drug, zidovudine
(azidothymidine, AZT), as the model substrate. In addition to
zidovudine (3 mM), the feed solution contained 1 mM NADPH
(endogenous co-substrate of cytochrome P450 reactions)
and 1 mM UDPGA (endogenous co-substrate of UDP-
glucuronosyltransferase reactions) in 0.1 mM Tris buffer (5
mM MgCl2, pH 7.5). This solution was fed to the oxygen
depletion unit (feed Q1, from the first syringe pump). The feed
of the IMER unit, in turn, comprised of the anoxic flow from
the oxygen depletion unit (Q2) and air-saturated flow from the
other end of the Y-junction (Q3, second syringe pump with
the same feed solution). The two syringe pumps were
programmable and interconnected so that the total flow rate
of the feed to the IMER unit (Q2 + Q3) could be kept constant.
In this study, a flow rate of 5 μL min−1 was used in the IMER
unit. The metabolites were quantitated by collecting 50 μL
fractions of the elute of the IMER unit (Q4) with the help of an
automated refrigerated fraction collector (CMA 470, CMA
Microdialysis AB, Kista, Sweden). The concentrations of the
zidovudine metabolites were quantitated using an ACQUITY
UPLC™ liquid chromatograph (LC, Waters, Milford, MA) and
Xevo TQ-S triple quadrupole mass spectrometer (MS, Waters,
Manchester, UK). The data were analyzed using MassLynx
V4.1 software. The LC and MS parameters and the method
validation results for AMT and AZT-G quantitation are
provided in the ESI† (Tables S1–S3 and Fig. S1 and S2).
Statistics
All results are presented as mean ± standard deviation from
repeated experiments, the number of which is indicated in
the context of each dataset. Statistical analysis and curve
fitting was performed using GraphPad Prism (GraphPad
Software, San Diego, CA) version 8.4.3.
Results and discussion
The inherent oxygen-scavenging capability of OSTEs has been
previously associated with the oxidation of thioether-linkages
in the polymer backbone of an OSTE+ formulation.22 The
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commercial OSTE+ formulation (Mercene Labs) includes a heat-
curable epoxy component in addition to the thiol and allyl
components. Similar thiol and allyl monomers are also common
in many custom OSTE formulations used in microfluidic devices,
including both cell-based and subcellular assays.26,29–31 In the
previous work,22 the oxygen scavenging rate was shown to
significantly decrease upon postprocessing of the bulk polymer
by heat, which increases the glass transition temperature (Tg),
and thus decreases the oxygen permeability, of the bulk
polymer.22 The oxygen depletion was thereby hypothesized to
result from the diffusion of the molecular oxygen to the bulk and
its subsequent reaction with the thioether groups in the polymer
backbone. However, the mechanism proposed for the OSTE+
formulation22 cannot readily explain the oxygen scavenging
observed in microchannels made of custom OSTE formulations,
which only contain the thiol and allyl monomers, but not the
thermo-responsive epoxy component of the OSTE+. According to
our preliminary findings, the oxygen depletion rate in custom
(only thiol- and allyl-containing) OSTE microhannels is similarly
impacted by heat treatment, even if the bulk properties (Tg,
oxygen permeability) do not change upon heating. Thus, in the
present study, we examined the OSTE-induced oxygen scavenging
in greater depth with the aim of understanding its mechanistic
basis, which is critical to both evaluating its feasibility to
biological microfluidics and drawing design principles for
microfluidic devices that exploit this unique property of OSTE
polymers.
Overall, photostructuring of OSTE-based microfluidic
devices can be done by, for instance, UV lithography,32 UV-
replica molding,29 3D printing,33 or roll-to-plate
manufacturing.34 Some of these techniques tend to result in
microscale compositional gradients upon monomer diffusion
in the bulk polymer yielding zones of densely crosslinked
polymer at highly illuminated areas and less quantitatively
crosslinked, highly off-stoichiometric polymer at low-
illuminated areas.32 In the UV-replica molding technique
used in this study, the monomer diffusion seemingly occurs
in vertical direction from the top surface (closer to the UV
source) toward the bottom surface (against the PDMS mold),
as illustrated in Fig. 1 (step iv). This conclusion was
supported by the fact that the off-stoichiometric
compositions typically showed two distinct glass transition
temperatures (Tg), whereas stoichiometric compositions gave
only a single Tg. It has also been experimentally shown in the
previous literature that the uncrosslinked, excess monomers
may be released from the bulk polymer, when incubated or
flushed with aqueous solvents.35,36 On the basis of the high
reactivity of thiols, we hypothesized that the inherent oxygen
scavenging capability of thiol-rich OSTE microdevices could
be the consequence of reactions between the released thiols
and molecular oxygen in the microchannel.
Mechanism of oxygen depletion by crosslinked thiol-enes
First, the impact of bulk polymer composition on the oxygen
depletion rate in UV-replica molded OSTE channels (2 × 30 ×
0.2 mm, w × h × L) was addressed by varying both the thiol-
monomer type and the thiol/allyl monomer ratio in the bulk.
In our experiments, we used tri-functional TATATO as the
allyl component and either a tri-functional TMPTMP or a
tetra-functional PETMP as the thiol component. The
monomer ratio varied from stoichiometric composition to a
50% molar excess of thiol functional groups over allyl groups
(Fig. 2C and D). Under static (no flow) conditions, the oxygen
depletion in OSTE microchannels made from either
TMPTMP- or PETMP-containing polymers followed first order
kinetics (Ln [O2] = −k × t + [O2]0). The rate constant of oxygen
depletion (k) was strongly dependent on the thiol/allyl
monomer ratio and increased along with increasing excess of
the thiol component in the bulk (ESI,† Table S4). The rate
constant (k) was also shown to be greater for PETMP-
containing polymers (Fig. 2C) than TMPTMP-containing
polymers (Fig. 2D).
Comparison of different bulk compositions gave further
support to our initial hypothesis that the mechanism of
oxygen depletion is likely associated with the oxidation of
uncrosslinked thiol monomers and the oxygen depletion rate
correlates with the amount of free (uncrosslinked) monomers
in the bulk. To confirm the hypothesis, the amount of the
uncrosslinked PETMP monomers was further manipulated by
using opposite excess (+25 mol%) of thiol and allyl functional
groups in the bulk (Fig. 2E). As expected, the use of allyl-rich
formulation decreased the rate constant substantially, as the
amount of uncrosslinked thiols in the bulk reduced to
minimum. On the other hand, adding photoinitiator
(Irgacure® TPO-L, 0.1% m/v) to the thiol-rich (+25 mol%)
formulation did not significantly change the oxygen
depletion rate in thiol-rich channels (Fig. 2E), even if the Tg
was substantially increased with the addition of the
photonitiator (13 → 42 °C). These observations confirmed
that the oxygen scavenging rate in custom OSTE channels
was mostly governed by the chemical composition of the
bulk, particularly the amount of uncrosslinked thiol
monomers, and was rather independent on the mechanical
bulk properties, such as Tg. In the absence of photoinitiator,
the monomer conversion (crosslinking) is typically
incomplete even for stoichiometric compositions,37,38 which
could explain the relatively high oxygen depletion rate in
microchannels fabricated with stoichiometric monomer
ratios. With the replication method used in this study, the
inner surface of the microchannel is furthest away from the
UV light source during the curing step, as illustrated in
Fig. 1. It is also known that the monomer conversion
decreases as a function of increasing layer depth.39 This
likely results in a relatively high amount of free monomers
next to the microchannel surface, which facilitates their
release to the microchannel and subsequent reaction with
molecular oxygen in the aqueous sample solution.
Similar to the previous work,22 heat treatment of the
microchannels (110 °C, overnight) after initial crosslinking
substantially reduced the oxygen depletion rate
(Fig. 2C and D). However, in the present study, this was
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associated with the vaporization of uncrosslinked thiol
monomers from the bulk, instead of changes in the oxygen
permeability of the bulk as proposed in the previous study.22
For example, the oxygen permeabilities of polymer
compositions featuring 50 mol% excess of thiols were 3.0 ±
0.007 cc cm m−2 per day atm−1 (TMPTMP–TATATO) and 1.0 ±
0.62 cc cm m−2 per day atm−1 (PETMP–TATATO). If oxygen
diffusion from inside the microchannel to the bulk polymer
was the most critical rate limiting step, the TMPTMP-
containing polymer should have showed a greater rate
constant (k) for oxygen depletion compared with the PETMP-
containing polymer, which is opposite to our observations
(Fig. 2C and D). Furthermore, the impact of the heat
treatment on Tg, which is known to correlate with the oxygen
permeability of the bulk,40 was practically insignificant in
case of both TMPTMP-containing (2.2 → −3.1 °C) and
PETMP-containing (25.9 → 26.6 °C) polymers (both +50%
molar excess of thiols).
These results further confirmed the hypothesis that
oxygen scavenging in OSTE microdevices is associated with
the reactions between uncrosslinked thiols, released from the
bulk, and molecular oxygen in the microchannel. Overall, the
oxygen permeabilities of the OSTE compositions used in this
study were approximately three orders of magnitude lower
than those reported for gas-permeable PDMS,41 which further
confirms that the oxygen diffusion within the crosslinked
OSTE network is negligible. Theoretically, however, the
greater oxygen permeability of TMPTMP-containing polymer
may improve the diffusion of ambient oxygen to the
microchannel compared with PETMP-containing polymers,
which could result in minor differences in the lowest
achievable oxygen partial pressures between compositions in
static conditions (Fig. 2C vs. D).
The rate-limiting step of OSTE-induced oxygen depletion
The apparent rate constants (k) of oxygen scavenging in the
OSTE microchannels for each polymer composition and post-
curing treatment tested are summarized in the ESI† (Table
S4). The data suggests that the rate of oxygen depletion is
dependent on the monomer-specific reaction kinetics or the
monomer diffusion kinetics from the bulk to the
microchannel, or both. To further examine the rate-limiting
step of oxygen depletion in OSTE microchannels, we
Fig. 3 Oxygen depletion rate in water solution in a closed container (V = 1 mL) by dissolved (A) PETMP and (B) TMPTMP monomers as a function
of time. (C) PETMP release rate in OSTE micropillar channels (A/V = 691 mm2/23 mm3 = 30 mm−1) made of PETMP and TATATO monomers with
25% molar excess of thiol functional groups. The free thiol functional groups were quantitated in static conditions by using DTNB (5,5′-dithiobis[2-
nitrobenzoic acid], “Ellman's reagent”), of which the molar concentration of the released tetrafunctional PETMP monomer was calculated. Error
bars denote standard deviation from n = 6 individual micropillar channels. (D) The effect of surface-to-volume ratio (A/V) on oxygen depletion
kinetics in OSTE channels in static conditions. Each data point represents the average of n = 3 individual channels. Both types of microchannels
were fabricated using PETMP and TATATO monomers with 25% molar excess of thiol functional groups.
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determined the rate constants for the reactions between
molecular oxygen and free TMPTMP or PETMP monomers
dissolved in an aqueous media in plastic microtubes (in
constant 1 mL sample volume). This experiment was
performed at high micromolar concentrations (100 and 1000
μM) and revealed that the oxygen depletion rate does not
markedly depend on the thiol monomer concentration
(Fig. 3A and B), until the thiol component is completely
consumed (e.g., at approximately 120 min in case of 100 μM
PETMP, Fig. 3A).
Next, the cumulative amount of thiols released from the
bulk polymer to the OSTE microchannel over time was
determined in a similar static (no flow) setting as the oxygen
depletion kinetics. These experiments were performed with
microchannels (n = 6) made of PETMP-containing polymer
with 25% molar excess of thiol functional groups. The
amount of thiols was titrated with the Ellman's reagent31
after 10, 20, and 30 min incubation, which confirmed that
the mass transfer of PETMP released from the bulk follows
first-order kinetics (Fig. 3C), similar to oxygen depletion in
OSTE microchannels in static conditions. On the basis of
these results, it was hypothesized that the thiol diffusion
across the polymer-liquid interface is the rate limiting step
for oxygen depletion in OSTE microchannels, and that the
diffusion rate is most dependent on the amount of
uncrosslinked thiols in the bulk. Consequently, the oxygen
depletion rate should also depend on the chip surface-to-
volume ratio. This hypothesis was further confirmed by
comparison of the rate constants derived from ‘unpacked’
microhannels with A/V = 6 mm−1 and micropillar channels
with A/V = 30 mm−1, both made of PETMP and TATATO using
25% molar excess of thiol functional groups. Comparison of
the oxygen depletion kinetics between these two designs, in
static conditions, confirmed that the rate coefficient k
increased with increasing surface-to-volume ratio (Fig. 3D).
The data also suggests that the oxygen depletion rate
correlates well with the surface-to-volume ratio, with
somewhat similar average rate constants (kA/V) between the
micropillar channels (5.1 ± 0.3 × 10−3 mm min−1) and the
unpacked channels (6.7 ± 0.3 × 10−3 mm min−1), when
proportioned to A/V.
Impact of flow rate on the oxygen depletion rate
The mechanistic studies of oxygen depletion in static
conditions laid the basis for rational microsystem design by
enabling precise control of the oxygen concentration on chip
with the help of microfluidic flow. Under flow conditions, the
system will not saturate in a similar manner as in static
conditions, but the flow rate also affects the reaction time
Fig. 4 The impact of flow rate and residence time on the air saturation level (%) at the end of (A) a single micropillar array (L = 30 mm) and (B) six
serially interconnected micropillar channel units (L = 6 × 30 mm). Red arrows denote the direction of the feed solution and the scanning electron
micrograph shows the detail of the micropillar array. Both types of microchannels were fabricated using PETMP and TATATO monomers with 25%
molar excess of thiol functional groups. Error bars denote standard deviation from n = 3 micropillar channels of each type.
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between molecular oxygen and the thiol monomers, and thus
defines the lowest achievable oxygen concentration. The
impact of flow rate on the oxygen concentration was
determined using two different designs of micropillar arrays
(A/V = 30 mm−1), including a 30 mm-long channel (Fig. 4A)
and its sextuplicate (L = 6 × 30 mm), in which six identical
micropillar arrays were monolithically integrated on a single
platform and serially connected via 10 mm-long transfer
channels (Fig. 4B). Both designs were made of PETMP-
containing polymer with 25% molar excess of thiol functional
groups. This experiment confirmed that, besides bulk
polymer composition, the oxygen concentration on chip can
be manipulated by controlling the residence time with the
help of the flow rate and/or the microchannel length
(Fig. 4A and B). On the basis of our results, the hypoxic
conditions could be maintained for at least 2.5 h under flow-
through conditions and the oxygen scavenging properties
were not markedly altered by storing of the microdevices at
room temperature prior to use for at least five days.
Recreating physiological oxygen levels on a microfluidic
device for in vitro drug metabolism assays
Based on the material and design characterizations, an
integrated, OSTE-based microdevice was developed for
controlling the on-chip oxygen concentration on demand
within a single microfluidic experiment. This chip design
featured six serially connected micropillar channels (oxygen
depletion unit) monolithically integrated, through a Y-
junction, with a seventh micropillar channel, which served as
the biological assay unit (Fig. 5A). With a view to drug
metabolism assays under hypoxic conditions, the biological
assay unit was functionalized sequentially with biotin,
streptavidin, and pre-biotinylated human liver microsomes
similar to previous work,26 to create an immobilized enzyme
reactor (IMER) that incorporates the key microsomal enzymes
that contribute to hepatic drug metabolism. In the IMER
unit, the flow rate also defines the enzymatic reaction rate.
According to our previous work, flow rate of 5 μL min−1 is
Fig. 5 Monolithic integration of an on-chip oxygen depletion unit with a microfluidic immobilized enzyme reactor (IMER). (A) Photograph of the
chip design comprising an oxygen depletion unit (filled with red dye), with an inlet Q1 and an outlet Q2, monolithically integrated with an
immobilized enzyme microreactor (IMER) unit (filled with green dye) with a Y-junction providing air-saturated feed solution from inlet Q3 and an
outlet Q4 for collecting metabolite samples. Oxygen level inside the microreactor was controlled by tuning the flow rate ratio of flows Q2
(oxygen-depleted) and Q3 (air-saturated). Red arrows denote the direction of the flow. The artificial color gradient of the red dye aims to visualize
oxygen scavenging in the oxygen depletion unit and the green dye the constant oxygen concentration in the IMER unit. (B) Measured vs.
theoretical oxygen concentration inside the IMER unit as a function of the percentual share of the air-saturated feed (Q3) of the total feed (Q2 +
Q3) to the IMER unit at constant total flow rate of 5 μL min
−1 (in the IMER unit). Error bars denote standard deviation from n = 3 chips. (C)
Schematic of the oxygen-sensitive metabolism of zidovudine (AZT). AMT = 3′-amino-3′-deoxythymidine, AZT-G = zidovudine glucuronide. (D)
Concentration of the oxygen-dependent metabolite (AMT) and the oxygen-independent metabolite (AZT-G) of zidovudine (AZT) at ambient (0–40
min and 80–100 min) and hypoxic (40–80 min) conditions. Hypoxic conditions were created by changing the feed from air-saturated flow (from
inlet Q3) to oxygen-depleted flow (from Q2) at t = 40 min. At 80 min, the oxygen supply was re-initiated by changing the feed back to air-
saturated flow from Q3. Flow rate during the experiment was constantly 5 μL min
−1. Error bars denote standard deviation of n = 4 chips.
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optimal for drug metabolism assays in a flow-through setting
with similar A/V.42 In this study, the total flow rate in the
IMER unit was thus kept constant at 5 μL min−1 and its
oxygen concentration was adjusted by changing the flow rate
ratio of the anoxic solution (Q2, 0% air saturation, from the
oxygen depletion unit) and an oxygen-rich solution (Q3, 100%
air saturation, from the other inlet of the Y-junction) to meet
the desired level (Fig. 5B). According to Fig. 4B, nearly anoxic
conditions (2.2 ± 0.9% air saturation) were achieved in the
oxygen depletion unit at a flow rate of 5 μL min−1, which
represents the maximum feed of Q2 (and zero-feed from Q3).
Lowering the flow rate in the oxygen depletion unit increases
the residence time and results in even lower air saturation
level so that at flow rates <5 μL min−1 the feed from Q2 was
always anoxic. Thus, the oxygen concentration of the
combined flow could be increased in a controlled manner
simply by increasing the relative share of the air-saturated Q3
feed solution. Further oxygen scavenging within the IMER
unit was considered negligible, because the residence time of
the combined flow (5 μL min−1) in the 30 mm-long IMER unit
was so short that the air saturation level decreased less than
10% (Fig. 4A). Furthermore, the surface biofunctionalization
in the IMER unit also decreased the oxygen depletion rate
compared with native surfaces (ESI,† Table S4). The mixing
efficiency of Q2 and Q3 was further confirmed by measuring
the air saturation % in the IMER unit at different ratios of Q2
and Q3, and comparing it with the theoretical air saturation%
calculated according to eqn (1):
Air saturation %ð Þ ¼ Q2
Qtotal
× 0% air saturation
þ Q3
Qtotal
× 100% air saturation (1)
in which Q2 is the flow rate of the anoxic feed solution from
the oxygen-depletion unit, Q3 is the flow rate of the air-
saturated feed solution from the Y-junction, and Qtotal is the
total, combined flow rate of Q2 and Q3. The correlation
between the measured and the theoretical air saturation level
was shown to be good (Fig. 5B), evidencing that the
physiological oxygen concentrations can be achieved and the
on-chip oxygen level controlled by simply adjusting the flow
rate ratio of Q2 and Q3.
As a proof of concept, the feasibility of the designed
microfluidic chip (Fig. 5A) for recreation of biologically
relevant oxygen concentrations in flow-through drug
metabolism assays was demonstrated with the help of an
antiviral drug, zidovudine (AZT). While the majority of AZT is
eliminated through glucuronidation into zidovudine-
glucuronide (AZT-G) in vivo, part of AZT is also metabolized
into a myelotoxic metabolite 3′-amino-3′-deoxythymidine
(AMT) by the reduction of the drug's azide group into an
amine (Fig. 5C).43 AMT production is known to elevate in
hypoxic conditions and it has been hypothesized to be
responsible for, e.g., the bone marrow suppression
encountered in patients receiving AZT therapy.8,44 To
demonstrate the impact of oxygen on AZT metabolism, the
on-chip oxygen level was controlled by switching the feed
solution at the entrance of the IMER unit from 100% of Q3
(air-saturated flow, 0–40 min) to 100% of Q2 (oxygen-depleted
flow, 40–80 min) and back to 100% of Q3 (air-saturated flow,
80–120 min). The total flow rate (Q2 + Q3) was kept constant
at 5 μL min−1. When conducting the flow-through
metabolism assays at ambient oxygen concentration (feed
from Q3 only), AZT was effectively glucuronidated to AZT-G
with an average rate of 6.2 ± 2.0 pmol min−1. As expected,
elimination of oxygen from the IMER feed (feed from Q2
only) increased the production rate of the cytotoxic AMT by
approximately 10-fold from initial 7.2 ± 4.2 pmol min−1 to 61
± 25 pmol min−1 (Fig. 5D). When the IMER feed was switched
back to the air-saturated flow (Q3 only), the AMT production
rate dropped back to its initial low level (Fig. 5D). In addition
to AMT, the formation of the AZT glucuronide was monitored
over the entire experiment as an internal control. As
expected, the impact of oxygen concentration on the AZT
glucuronidation was shown to be somewhat negligible
(Fig. 5D).
The proof-of-concept demonstration with AZT highlights
the importance of oxygen control in biological assays. The
chip design developed in this study could pave the way for
higher throughput screening of the metabolic profiles of drug
candidates at varying oxygen conditions in vitro. For example,
the production rate of the toxic metabolite of AZT is
significantly underestimated if only determined in ambient
oxygen conditions using conventional in vitro assays. The
possibility to adjust the oxygen concentration independent of
the total flow rate, as demonstrated in this study, is
particularly useful with a view to enzyme kinetic
determinations under flow-through conditions, which
necessitate precise control over residence (reaction) times.42
In this study, a total flow rate of 5 μL min−1 was used in the
biological assay unit, but the same assay configuration is
generally applicable to a wide range of flow rates, by
adjusting the design (residence time, A/V) of the oxygen
depletion unit so that oxygen is fully scavenged before the
biological assay unit. If needed, the capacity of the oxygen
depletion unit may be further adjusted by manipulating the
bulk composition, which defines the rate constant of oxygen
depletion.
Conclusion
This work addressed the mechanistic basis of material-
induced oxygen depletion in aqueous solutions on
microfluidic devices made of OSTE polymers. The inherent
oxygen scavenging of the OSTE compositions used in this
study was strongly associated with the reactions of the
uncrosslinked thiol monomers, released from the bulk
polymer, with molecular oxygen at the polymer-liquid
interface in the microchannel. The oxygen depletion in OSTE
microchannels was shown to follow first order kinetics, with
the rate constant being dependent on the type and relative
amount of the thiol monomer used in the bulk composition.
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The rate-limiting step of oxygen depletion was shown to be
the kinetics of the thiol monomer diffusion from the bulk to
the microchannel. Thus, under flow-through conditions, the
oxygen depletion rate constant was proportional to the
surface-to-volume ratio and the residence time determined by
the microfluidic flow rate. This eventually enabled the
rational design of OSTE-based microfluidic devices for
controlling the on-chip oxygen concentration on demand.
This study specifically addressed the craving need for new
in vitro tools that could facilitate rapid screening of drug
metabolism (molecular biotransformations) in normoxic and
hypoxic conditions using microsomal enzymes (subcellular
assays). For this purpose, we developed an integrated
microfluidic chip comprising distinct oxygen depletion and
immobilized enzyme microreactor units, and demonstrated
the impact of oxygen on the formation of the cytotoxic
metabolite of zidovudine in a single microfluidic experiment
within 2 h. Similarly fast temporal control over oxygen level
is difficult to achieve in traditional laboratory settings and
thus the impact of oxygen on drug metabolism is often
ignored in the current state-of-the art (static) microsomal
in vitro assays. Theoretically, similar chip configuration may
be exploited to microfluidic cell-based assays as well,
although care should be taken to ensure that the thiol
monomers released from the bulk do not interfere with cell
viability and proliferation.
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